Kim, Do Young and Toan, Bao Nguyen and Tan, Chee-Kiat and Hasan, Irsan and Setiawan, Lyana and Yu, Ming -Lung and Izumi, Namiki and Huyen, Nguyen Nguyen and Chow, Pierce Kah-Hoe and Mohamed, Rosmawati and Chan, Stephen Lam and Tanwandee, Tawesak and Lee, Teng-Yu and Hai, Thi Thanh Nguyen and Yang, Tian and Lee, Woo -Chang and Chan, Henry Lik Yuen (2023) Utility of combining PIVKA-II and AFP in the sur- veillance and monitoring of hepatocellular carci- noma in the Asia-Pacific region. Clinical and Molecular Hepatology, 29 (2). pp. 277-292. ISSN 2287-2728, DOI https://doi.org/10.3350/cmh.2022.0212.
Full text not available from this repository.Abstract
Even though the combined use of ultrasound (US) and alpha-fetoprotein (AFP) is recommended for the surveillance of hepatocellular carcinoma (HCC), the utilization of AFP has its challenges, including accuracy dependent on its cut-off levels, degree of liver necroinflammation, and etiology of liver disease. Though various studies have demonstrated the utility of protein induced by vitamin K absence II (PIVKA-II) in surveillance, treatment monitoring, and predicting recurrence, it is still not recommended as a routine biomarker test. A panel of 17 experts from Asia-Pacific, gathered to discuss and reach a consensus on the clinical usefulness and value of PIVKA-II for the surveillance and treatment monitoring of HCC, based on six predetermined statements. The experts agreed that PIVKA-II was valuable in the detection of HCC in AFP-negative patients, and could potentially benefit detection of early HCC in combination with AFP. PIVKA-II is clinically useful for monitoring curative and intra-arterial locoregional treatments, outcomes, and recurrence, and could potentially predict microvascular invasion risk and facilitate patient selection for liver transplant. However, combining PIVKA-II with US and AFP for HCC surveillance, including small HCC, still requires more evidence, whilst its role in detecting AFP-negative HCC will potentially increase as more patients are treated for hepatitis-related HCC. PIVKA-II in combination with AFP and US has a clinical role in the Asia-Pacific region for surveillance. However, implementation of PIVKA-II in the region will have some challenges, such as requiring standardization of cut-off values, its cost-effectiveness and improving awareness among healthcare providers. (Clin Mol Hepatol 2023;29:277-292)
| Item Type: | Article |
|---|---|
| Funders: | Roche Diagnostics |
| Uncontrolled Keywords: | PIVKA-II; Alpha-fetoprotein; Carcinoma; Hepatocellular; Consensus; Biomarkers |
| Subjects: | R Medicine R Medicine > RC Internal medicine |
| Divisions: | Faculty of Medicine |
| Depositing User: | Ms Zaharah Ramly |
| Date Deposited: | 26 Nov 2024 08:30 |
| Last Modified: | 26 Nov 2024 08:30 |
| URI: | http://eprints.um.edu.my/id/eprint/38343 |
Actions (login required)
 |
View Item |
